Tudor Investment Corp
MRNS

Tudor Investment Corp’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Tudor Investment Corp’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-9,002
Closed -$103K – 1308
2018
Q4 		$103K Buy
+9,002
New +$182K ﹤0.01% 925

Other funds holding MRNS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Tudor Investment Corp's MRNS Position: Q1 2019 in Review

Tudor Investment Corp sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2019, closing a stake of 9,002 shares — an estimated $103K sold.

Tudor Investment Corp first reported a position in MRNS in Q4 2018 and held it in 1 quarter. The position peaked at $103K in Q4 2018. 81 funds tracked by Wall St. Rank hold MRNS as of Q1 2019.

  • Tudor Investment Corp reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2019 after selling out during the quarter.
  • Tudor Investment Corp sold 9,002 Marinus Pharmaceuticals, Inc shares in Q1 2019, an estimated $103K.
  • Tudor Investment Corp first reported a position in Marinus Pharmaceuticals, Inc in Q4 2018 and held it in 1 quarter.
  • Tudor Investment Corp's Marinus Pharmaceuticals, Inc position peaked at $103K in Q4 2018.
  • 81 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2019.

Based on Tudor Investment Corp's 13F filing for Q1 2019, filed 15 May 2019.